# BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

> **NCT06032936** · PHASE1 · TERMINATED · sponsor: **LianBio LLC** · enrollment: 4 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** BBP-398
- **DRUG:** osimertinib

## Key facts

- **NCT ID:** NCT06032936
- **Lead sponsor:** LianBio LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-27
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-03-29
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Business reason
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06032936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06032936, "BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06032936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*